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Introduction
Antiphospholipid syndrome (APS) is characterized by
venous or arterial thrombosis and/or fetal losses, in the
presence of one or more types of antiphospholipid anti-
bodies (aPL) (Anitcardiolipin antibodies (ACA), lupus
anticoagulant (LA) or anti beta 2-glycoprotein I (b2GPI).
Information about APS in juvenile patients is limited and
reports showed some differences between the clinical and
serological features in adults and juvenile APS. There are
limited data on the incidence and prevalence of Primary
APS (PAPS) and Secondary APS (SAPS). Thrombotic
events are the typical manifestation of APS but hematolo-
gic and neurologic manifestations have been described
with different frequencies.
Objectives
To describe a group of juvenile patients with APS and
to compare the clinical and serological manifestations of
PAPS and SAPS.
Methods
This is a descriptive case series study. Includes patients
from three pediatric rheumatology clinics in Bogota and
Cali, Colombia.
Results
There were 69 APS juvenile patients. Sex ratio: F 5.9:
M 1. Mean age at onset: 12.3 years (2-17 years). Mean
follow up 30 months (5-120). Antinuclear antibodies
were positive in 83%, IgG ACA 73%, IgM ACA 74% and
LA 58%. Anti b2GPI was not measured in all patients.
41% developed one or more thrombotic events, 93%
developed thrombotic and no thrombotic manifestations
and 58% had two or more non thrombotic manifesta-
tions. 28/69 patients developed 44 thrombotic events
during follow up. Two juvenile Systemic Lupus Erythe-
matous (jSLE) patients developed catastrophic APS. Deep
venous thrombosis (DVT) was more common in PAPS
and arterial thrombosis was more frequent on SAPS
without statistical significance (p 0.209 and 0.299). Arter-
ial thrombosis was documented on 16 patients (pulmon-
ary thromboembolism, cerebrovascular events, peripheral
arterial thrombosis and bone and liver infarcts) but there
were not significant differences on frequency and type of
thrombosis between PAPS and SAPS. 29% had recur-
rences of thrombosis without significant differences
between PAPS and SAPS (p value 0.134).
Thrombocytopenia was the most common non throm-
botic manifestation and was more frequent on PAPS
while hemolytic anemia was more common SAPS (p
values 0, 05 and 0,058). Neurological complications had
a similar frequency on both groups. Raynaud and livedo
reticularis were more common on SAPS but p values
were not significant. Auto antibodies profile were also
very similar on PAPS and SAPS. All types of aPL were
detected on PAPS and SAPS with a similar frequency
on patients with and without thrombosis.
Conclusion
APS may determine an important morbidity. Is a fre-
quent cause on thrombosis in juvenile patients who may
have or not an auto immune disease like jSLE. Non
thrombotic symptoms are very common on PAPS and
SAPS. Hematologic, neurological and skin manifesta-
tions are frequent on both groups. All types of aPL were
detected on PAPS and SAPS and the frequency was
similar on patients who developed thrombosis and who
do not. Screening of aPL on patients with thrombosis
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and hematological, neurological and dermatological
complications as described must be performed on a reg-
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